CD4+T cells eliminate MHC class II-negative cancer cellsin vivoby indirect effects of IFN-γ
- 20 July 1999
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (15) , 8633-8638
- https://doi.org/10.1073/pnas.96.15.8633
Abstract
CD4+T cells can eliminate tumor cellsin vivoin the absence of CD8+T cells. We have CD4+T cells specific for a MHC class II-restricted, tumor-specific peptide derived from a mutant ribosomal protein expressed by the UV light-induced tumor 6132A-PRO. By using neutralizing mAb specific for murine IFN-γ and adoptive transfer of CD4+T cells into severe combined immunodeficient mice, we show that anti-IFN-γ treatment abolishes the CD4+T cell-mediated rejection of the tumor cellsin vivo. The tumor cells were MHC class II negative, and IFN-γ did not induce MHC class II expressionin vitro. Therefore, the tumor-specific antigenic peptide must be presented by host cells and not the tumor cells. Tumor cells transduced to secrete IFN-γ had a markedly reduced growth rate in severe combined immunodeficient mice, but IFN-γ did not inhibit the growth of the tumor cellsin vitro. Furthermore, tumor cells stably expressing a dominant-negative truncated form of the murine IFN-γ receptor α chain, and therefore insensitive to IFN-γ, nevertheless were rejected by the adoptively transferred CD4+T cells. Thus, host cells, and not tumor cells, seem to be the target of IFN-γ. Together, these results show that CD4+T cells can eliminate IFN-γ-insensitive, MHC class II-negative cancer cells by an indirect mechanism that depends on IFN-γ.Keywords
This publication has 46 references indexed in Scilit:
- Tumor Cell Responses to IFNγ Affect Tumorigenicity and Response to IL-12 Therapy and AntiangiogenesisImmunity, 1998
- Synergy between Interferon-γ and Tumor Necrosis Factor-α in Transcriptional Activation Is Mediated by Cooperation between Signal Transducer and Activator of Transcription 1 and Nuclear Factor κBJournal of Biological Chemistry, 1997
- CELLULAR RESPONSES TO INTERFERON-γAnnual Review of Immunology, 1997
- Biological Implications of HLA‐DR Expression in TumoursScandinavian Journal of Immunology, 1995
- A unique tumor antigen produced by a single amino acid substitutionImmunity, 1995
- Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cellsInternational Journal of Cancer, 1994
- Presence on a human melanoma of multiple antigens recognized by autologous CTLInternational Journal of Cancer, 1989
- Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.The Journal of Experimental Medicine, 1987
- Multiple tumour-specific antigens expressed on a single tumour cellNature, 1983
- Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.The Journal of Experimental Medicine, 1982